Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HOOK - Hookipa Pharma Inc


IEX Last Trade
5.11
-0.100   -1.957%

Share volume: 11,401
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$5.21
-0.10
-1.92%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
34%
Profitability 25%
Dept financing 10%
Liquidity 66%
Performance 42%
Company vs Stock growth
vs
Performance
5 Days
-1.69%
1 Month
-9.20%
3 Months
-30.42%
6 Months
-34.63%
1 Year
-22.11%
2 Year
-63.43%
Key data
Stock price
$5.11
P/E Ratio 
-1.04
DAY RANGE
N/A - N/A
EPS 
-$5.37
52 WEEK RANGE
$4.10 - $11.30
52 WEEK CHANGE
-$0.23
MARKET CAP 
50.496 M
YIELD 
N/A
SHARES OUTSTANDING 
9.655 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$17,561
AVERAGE 30 VOLUME 
$27,207
Company detail
CEO:
Region: US
Website: hookipabiotech.com
Employees: 133
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a

Recent news